Skip to main content

Market Overview

Roth Still Loves Galmed Pharma, Keeps $20 Price Target And 'Buy' Rating


Shares of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) fell 3.34 percent on Wednesday, after the company announced the “inlicensing of a companion diagnostic test candidate for the co-development with the company's drug Aramchol for the treatment of NASH," according to a new note from Roth Capital.

Following the event, Roth analyst Elemer Piros reiterated a Buy rating and a $20.00 12-month price target on the stock, which implies that he expects the stock to more than double in value over the next year.

Liver Diagnostics

The current method available for diagnosis and measurement of a drug effect in the NASH (nonalcoholic steatohepatitis) indication involves an invasive liver biopsy.

As far as Roth knows, Galmed is the first company to make public a formal development of a companion diagnostic for a drug in this indication.

Licensor and co-developmental partner, One Way Liver Genomics has developed a test (OWLiver®) that should identify NASH patients. In a paper published not long ago, the researchers involved in the trial said that, “with a panel of 540 serum metabolites NASH could be predicted with a sensitivity of 0.71 and a specificity of 0.92.”

Now, where does Galmed come in here?

The company is expected to co-fund the ongoing Phase 2b trial (ARREST) clinical trial with up to €437,000. The aim is to identify “whether these or perhaps additional biomarkers could identify Aramchol responders.”

Assuming launch in 2020, Roth estimates that Aramchol may reach roughly $3 billion in annual peak sales by 2024.

Latest Ratings for GLMD

Mar 2021HC Wainwright & Co.MaintainsBuy
Jan 2021Raymond JamesMaintainsOutperform
Nov 2020Canaccord GenuityMaintainsBuy

View More Analyst Ratings for GLMD
View the Latest Analyst Ratings


Related Articles (GLMD)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Reiteration Analyst Ratings Trading Ideas

Latest Ratings

ETCredit SuisseMaintains13.0
IFRXCredit SuisseMaintains2.8
METCredit SuisseMaintains68.0
FLXNCredit SuisseMaintains14.0
ENPHCapital OneInitiates Coverage On175.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at